Starpharma Holdings Limited · ASX:SPL
Starpharma — Shareholder Meeting (November 2001)
18 slides from Starpharma's shareholder meeting presentation, Nov 15, 2001
Slide 1: Starpharma
Staip alina ss aN www.starpharma.com
Slide 2: Starpharma Highlights
Starpharma Highlights • Establishment of Dendritic Nanotechnologies Limited in • collaboration with PANBIO Ltd • Significant Development Progress: - Antivirals - Anti-cancer - Bioprotective agents • Establishment of in-house drug development team including quality assurance/regulatory skills • Inter
Slide 3: New Premises
New Premises
Slide 4: International R&D Network
International R&D Network Czech Republic 1 Belgium 1 Canada 2 Australia 10 USA 15
Slide 5: Nanotechnology Revolution
SCIENTIFIC seccu. AMERICAN © EE THE BUSINESS OF INNOVATION Medical Nanoprobes Atom-Moving Tools i COULD Buckytube Electronics New Laws of Physics fj H A N Living Machinery Nano Science Fiction i CHANGE The Science of the Small Gets Down to Business : H NANOMATERIALS Eric Drexler on Nanorobots ! and
Slide 6: Nanotechnology & Dendrimers
Nanotechnology & Dendrimers 1 billionth meter Nanoscale 100 billionth meter Defined uniform Structures Conventional Biological Molecules Drugs Dendrimers Bucky Balls Viruses & Bacteria Small Nanotechnology Large Products Molecules Mechanical getting bigger devices getting smaller
Slide 7: Active Groups
3 Active Groups 4 Aa Metin for bioavailability/cell penetration Tissue/Organ targeting &
Slide 8: Polyvalent Drug Design
Polyvalent Drug Design Multiple Binding Vs Single Binding
Slide 9: Dendrimers are capable of polyvalent binding to cell or viral receptors
Dendrimers are capable of polyvalent (multiple receptor-site) binding to cell or viral receptors.
Slide 10: Most small molecule drugs are only capable of monovalent binding
Most small molecule drugs are only capable of monovalent binding.
Slide 11: Dendrimer Technology
Dendrimer Technology • Active against a wide range of diseases • Increases biological interaction • Can be combined with other drugs • Uniform, easily modified and predictable • Low toxicity • Not rejected by the body
Slide 12: Starpharma Intellectual Property
Starpharma Intellectual Property Title Stage Antiviral Dendrimers Granted Aust, N.Z., Singapore and USA Angiogenic Inhibitory Compounds Granted Aust, N.Z. and Singapore Antiviral Linear Polymers Granted Aust and N.Z. Inorganic Antiviral Compounds Pending U.S. Antimicrobial & Antiparasitic Agents Ent
Slide 13: Capturing Value
Capturing Value • Taking products through development. - Prevention & treatment of sexually transmitted diseases - Anticancer - Bioprotection • Leveraging IP position through licensing and partnering with others. • Co-investment in U.S. based Dendritic Nanotechnologies Limited (DNT).
Slide 14: Product Development
Product Development Discovery Pre-clinical Testing Clinical Trials License to 1-2 years major Basic Phases I & II pharmaceutical Chemistry Test for efficacy, side Research Up to 2 years company effects and metabolism FDA Lead Compound Approval Selection STD Prevention (Vaginal Microbicide) Genital H
Slide 15: Woodchuck Trials – Hepatitis/Liver Cancer
Woodchuck Trials – Hepatitis/Liver Cancer The accepted working animal model for Hepatitis B virus (HBV) is the woodchuck and HBV infections cause liver cancer in these animals. Trials on HBV infected woodchucks in the US have commenced. Possibility that one drug may inhibit hepatitis B virus and liv
Slide 16: Bioprotection
Bioprotection (1) Respiratory Virus Bioprotection (2) Toxin Bioprotection
Slide 17: Market Potential
Market Potential Incidence Potential Market Viral Infections 14 million people each year US$8 billion+ each year Angiogenesis 1.22 million people in US in US$7.8 billion in 2000 (Cancer) 2000 Toxins 124 000 deaths from cholera US$2 billion+ each year each year Hepatitis B 350 million people infected
Slide 18: Starpharma Key Strengths
Starpharma Key Strengths • Strong development focus • Major international collaborative network • External validation of platform technology • Highly skilled dendrimer chemistry teams • Extensive discovery pipeline • Strong patent position • Leading position in nanotechnology • Potential for major i
Starpharma Holdings — Shareholder Meeting (November 2001) on 6ix